EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

GP ‐2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP‐Kinase and impairs the NF‐kB pathway in pancreatic cancer cells

Britta Majchrzak-Stiller iD, Marie Buchholz, Ilka Peters, Daniel Waschestjuk, Johanna Strotmann, Philipp Höhn, Stephan Hahn, Chris Braumann, Waldemar Uhl, Thomas Müller, Hanns Möhler

Journal of Cellular and Molecular Medicine · 2023

DOI: 10.1111/jcmm.17825 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2023. Verfasst von Britta Majchrzak-Stiller und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of General and Visceral Surgery, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany. Hauptthemen laut MEDLINE: Antineoplastic Agents, Pancreatic Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Geistlich Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

GP‐2250, a novel anticancer agent, severely limits the energy metabolism, as demonstrated by the inhibition of hexokinase 2 and glyceraldehyde‐3‐phosphate dehydrogenase and a decrease of ATP. Rescue experiments with supplementary pyruvate or oxaloacetate demonstrated that a TCA cycle deficit largely contributed to cytotoxicity. Activation of the energy‐deficit sensor, AMP‐dependent protein kinase, was associated with increased phosphorylation of acetyl‐CoA carboxylase and Raptor, pointing to a possible deficit in the synthesis of fatty acids and proteins as essential cell components. Binding of p65 to DNA was dose‐dependently reduced in nuclear lysates. A transcriptional deficit of NF‐κB (nuclear factor kappa‐light‐chain‐enhancer of activated B cells) was substantiated by the downregulation of cyclin D1 and of the anti‐apoptotic Bcl2, in line with reduction in tumour cell proliferation and induction of apoptosis, respectively. The upregulation of p53 concomitant with an excess of ROS supported apoptosis. Thus, the anticancer activity of GP‐2250 is a result of disruption of energy metabolism and inhibition of tumour promotion by NF‐κB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsPancreatic NeoplasmsHumansNF-kappa BAdenylate KinaseI-kappa B KinaseCell Line, TumorApoptosisPhosphorylationEnergy Metabolism

Stichwörter der Autor:innen

GP-2250NFκBROSaerobic glycolysisapoptosispancreatic cancerproliferation

Substanzen

NF-kappa BAdenylate KinaseI-kappa B KinaseAntineoplastic Agents

Autor:innen und Institutionen

  • Department of General and Visceral Surgery, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.
  • Department of Molecular Gastrointestinal Oncology, Ruhr-University Bochum, Bochum, Germany.
  • Department of General, Visceral and Vascular Surgery, Evangelische Kliniken Gelsenkirchen, Akademisches Lehrkrankenhaus der Universität Duisburg-Essen, Gelsenkirchen, Germany.
  • Geistlich Pharma AG, Lucerne, Switzerland.
  • Institute of Pharmacology, University of Zurich and Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH), Zurich, Switzerland.

ORCID-Profile: Britta Majchrzak-Stiller

Förderung

  • Geistlich Pharma

Zitieren

APA

Majchrzak-Stiller, B., Buchholz, M., Peters, I., Waschestjuk, D., Strotmann, J., Höhn, P., Hahn, S., Braumann, C., Uhl, W., Müller, T., & Möhler, H. (2023). GP ‐2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP‐Kinase and impairs the NF‐kB pathway in pancreatic cancer cells. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.17825

Vancouver

Majchrzak-Stiller B, Buchholz M, Peters I, Waschestjuk D, Strotmann J, Höhn P, et al. GP ‐2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP‐Kinase and impairs the NF‐kB pathway in pancreatic cancer cells. Journal of Cellular and Molecular Medicine. 2023. doi:10.1111/jcmm.17825

BibTeX
@article{MajchrzakStiller2023,
  author = {Majchrzak-Stiller, Britta and Buchholz, Marie and Peters, Ilka and Waschestjuk, Daniel and Strotmann, Johanna and Höhn, Philipp and Hahn, Stephan and Braumann, Chris and Uhl, Waldemar and Müller, Thomas and Möhler, Hanns},
  title = {GP ‐2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP‐Kinase and impairs the NF‐kB pathway in pancreatic cancer cells},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2023},
  doi = {10.1111/jcmm.17825}
}
Kostenlos starten →